-  Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe  -

Excerpt from:
SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh